English

Verona Pharma PLC

EDGAR

VRNA Quarterly report (10-Q) · filed 2025-08-06

Annual consolidated revenue for 2024: about USD 42.28M, using the latest reported figures. The previous period, 2023, was about USD 0.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

103 million USD

2025 Q2 · USD

Exact inputs and evidence

Revenue: 103138000 USD Source

Operating margin

12.9%

2025 Q2 · %

Exact inputs and evidence

Operating Income: 13305000 USD Source
Revenue: 103138000 USD Source

Operating cash flow

30.6 million USD

2025 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 19000000 USD Source
Operating Cash Flow: -11561000 USD Source

Free cash flow

30.6 million USD

2025 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 19000000 USD Source
Operating Cash Flow: -11561000 USD Source
Capital Expenditure: 535000 USD Source
Capital Expenditure: 535000 USD Source

Cash and cash equivalents: 438 million USD 2025-06-30 Source
Exact value

438016000 USD
Long-term debt including current maturities: 50 million USD 2023-12-31 Source
Exact value

50000000 USD
Shares outstanding: 688 million shares 2025-06-30 Source
Exact value

687930486 shares

Reported share-count change

6.06% · 39.3 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

648654174 shares · 2024-06-30· Source
687930486 shares · 2025-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

222 million USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Revenue: 5624000 USD · 2024-07-01 – 2024-09-30 Source
Revenue: 42279000 USD · 2024-01-01 – 2024-12-31 Source
Revenue: 5624000 USD · 2024-01-01 – 2024-09-30 Source
Revenue: 76256000 USD · 2025-01-01 – 2025-03-31 Source
Revenue: 103138000 USD · 2025-04-01 – 2025-06-30 Source

Net income

-81.2 million USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Net income: -42962000 USD · 2024-07-01 – 2024-09-30 Source
Net income: -173418000 USD · 2024-01-01 – 2024-12-31 Source
Net income: -139591000 USD · 2024-01-01 – 2024-09-30 Source
Net income: -16319000 USD · 2025-01-01 – 2025-03-31 Source
Net income: 11921000 USD · 2025-04-01 – 2025-06-30 Source

Operating cash flow

-72.5 million USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Operating cash flow: -93367000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -30712000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -122203000 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -93367000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -11561000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: 19000000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -11561000 USD · 2025-01-01 – 2025-03-31 Source

Capital expenditure

1.07 million USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Capital expenditure: 45000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 45000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 580000 USD · 2024-01-01 – 2024-12-31 Source
Capital expenditure: 45000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 535000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 535000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 535000 USD · 2025-01-01 – 2025-03-31 Source

Free cash flow

-73.6 million USD

2024-07-01 – 2025-06-30

Exact inputs and evidence

Operating cash flow: -93367000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -30712000 USD · 2024-01-01 – 2024-06-30 Source
Operating cash flow: -122203000 USD · 2024-01-01 – 2024-12-31 Source
Operating cash flow: -93367000 USD · 2024-01-01 – 2024-09-30 Source
Operating cash flow: -11561000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: 19000000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -11561000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 45000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 45000 USD · 2024-01-01 – 2024-06-30 Source
Capital expenditure: 580000 USD · 2024-01-01 – 2024-12-31 Source
Capital expenditure: 45000 USD · 2024-01-01 – 2024-09-30 Source
Capital expenditure: 535000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 535000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 535000 USD · 2025-01-01 – 2025-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2025-08-06.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2024-12-31
Operating income: 6 of 11 periods available· newest 2024-12-31
Net income: 6 of 11 periods available· newest 2024-12-31
Operating cash flow: 6 of 11 periods available· newest 2024-12-31
Capital expenditure: 6 of 11 periods available· newest 2024-12-31
Total assets: 5 of 11 periods available· newest 2024-12-31
Total liabilities: 5 of 11 periods available· newest 2024-12-31
Current assets: 5 of 11 periods available· newest 2024-12-31
Current liabilities: 5 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2024-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2023-12-31
Shares outstanding: 5 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+USD 42.28 million

Prior period

USD 0

2023-01-01 – 2023-12-31
Current period

USD 42.28 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

42279000 − 0 = 42279000 USD

0 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
42279000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Verona Pharma PLC · 2024-12-31 Verona Pharma PLC (edgar:1657312) Year-over-year change in Revenue: 42279000 USD Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 42279000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1216476 Filing: 000165731225000010 Input fundies:Revenue: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1217094 Filing: 000165731225000010
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 119.05 million

Prior period

−USD 54.37 million

2023-01-01 – 2023-12-31
Current period

−USD 173.42 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-173418000 − -54369000 = -119049000 USD

-54369000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-173418000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Verona Pharma PLC · 2024-12-31 Verona Pharma PLC (edgar:1657312) Year-over-year change in Net income: -119049000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -173418000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1833552 Filing: 000165731225000010 Input fundies:NetIncome: -54369000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1834327 Filing: 000165731225000010
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 71.98 million

Prior period

−USD 50.22 million

2023-01-01 – 2023-12-31
Current period

−USD 122.2 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-122203000 − -50222000 = -71981000 USD

-50222000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-122203000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Verona Pharma PLC · 2024-12-31 Verona Pharma PLC (edgar:1657312) Year-over-year change in Operating cash flow: -71981000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -122203000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1428588 Filing: 000165731225000010 Input fundies:OperatingCashFlow: -50222000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1429245 Filing: 000165731225000010
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+USD 580,000

Prior period

USD 0

2023-01-01 – 2023-12-31
Current period

USD 580,000

2024-01-01 – 2024-12-31

Exact inputs and evidence

580000 − 0 = 580000 USD

0 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
580000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Verona Pharma PLC · 2024-12-31 Verona Pharma PLC (edgar:1657312) Year-over-year change in Capital expenditure: 580000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 580000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1431555 Filing: 000165731225000010 Input fundies:CapitalExpenditure: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1432117 Filing: 000165731225000010
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue USD 42.28 million 100% of revenue
Operating costs Derived USD 196.91 million 466% of revenue
Operating income −USD 154.63 million −366% of revenue
Tax, interest and other Derived USD 18.79 million 44% of revenue
Net income −USD 173.42 million −410% of revenue

Cash

Operating cash flow −USD 122.2 million −289% of revenue
Capital expenditure USD 580,000 1.4% of revenue
Free cash flow Derived −USD 122.78 million −290% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Operating loss: operating costs were 283% of revenue.
2022 Operating loss: operating costs were 16,639% of revenue.
2023 Not shown: operating income or net income is not reported.
2024 Operating loss: operating costs were 466% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	0	74277000 Derived	-74277000	-9131000 Derived	-65146000	-45158000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -74277000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -65146000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -45076000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 82000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	40000000	113313000 Derived	-73313000	-17744000 Derived	-55569000	-33266000 Derived	Source 2021-01-01 – 2021-12-31: 40000000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -73313000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -55569000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -33254000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 12000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	458000	76208000 Derived	-75750000	-7049000 Derived	-68701000	-59891000 Derived	Source 2022-01-01 – 2022-12-31: 458000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -75750000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -68701000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -59862000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 29000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	0	67569000 Derived	-67569000	-13200000 Derived	-54369000	-50222000 Derived	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -67569000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -54369000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -50222000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 0 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	42279000	196906000 Derived	-154627000	18791000 Derived	-173418000	-122783000 Derived	Source 2024-01-01 – 2024-12-31: 42279000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -154627000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -173418000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -122203000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 580000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 42.3M 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	40000000	Revenue: 40000000 Open source
20222022-12-31	Revenue	458000	Revenue: 458000 Open source
20232023-12-31	Revenue	0	Revenue: 0 Open source
20242024-12-31	Revenue	42279000	Revenue: 42279000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 40000000 Open source Revenue: 0 Open source
20222022-12-31	Year over year	-98.9%	Revenue: 458000 Open source Revenue: 40000000 Open source
20232023-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 458000 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 42279000 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -365.7% 2024

Net margin -410.2% 2024

Free cash flow margin -290.4% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	Not reported	Operating Income: -74277000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	-183.3%	Operating Income: -73313000 Open source Revenue: 40000000 Open source
20222022-12-31	Operating margin	-16,539.3%	Operating Income: -75750000 Open source Revenue: 458000 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -67569000 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	-365.7%	Operating Income: -154627000 Open source Revenue: 42279000 Open source
20202020-12-31	Net margin	Not reported	Net Income: -65146000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	-138.9%	Net Income: -55569000 Open source Revenue: 40000000 Open source
20222022-12-31	Net margin	-15,000.2%	Net Income: -68701000 Open source Revenue: 458000 Open source
20232023-12-31	Net margin	Not reported	Net Income: -54369000 Open source Revenue: 0 Open source
20242024-12-31	Net margin	-410.2%	Net Income: -173418000 Open source Revenue: 42279000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -45076000 Open source Capital Expenditure: 82000 Open source
20212021-12-31	Free cash flow margin	-83.2%	Revenue: 40000000 Open source Operating Cash Flow: -33254000 Open source Capital Expenditure: 12000 Open source
20222022-12-31	Free cash flow margin	-13,076.6%	Revenue: 458000 Open source Operating Cash Flow: -59862000 Open source Capital Expenditure: 29000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -50222000 Open source Capital Expenditure: 0 Open source
20242024-12-31	Free cash flow margin	-290.4%	Revenue: 42279000 Open source Operating Cash Flow: -122203000 Open source Capital Expenditure: 580000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -122.2M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-45076000	Operating Cash Flow: -45076000 Open source
20212021-12-31	Operating cash flow	-33254000	Operating Cash Flow: -33254000 Open source
20222022-12-31	Operating cash flow	-59862000	Operating Cash Flow: -59862000 Open source
20232023-12-31	Operating cash flow	-50222000	Operating Cash Flow: -50222000 Open source
20242024-12-31	Operating cash flow	-122203000	Operating Cash Flow: -122203000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -122.8M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-45158000	Operating Cash Flow: -45076000 Open source Capital Expenditure: 82000 Open source
20212021-12-31	Free cash flow	-33266000	Operating Cash Flow: -33254000 Open source Capital Expenditure: 12000 Open source
20222022-12-31	Free cash flow	-59891000	Operating Cash Flow: -59862000 Open source Capital Expenditure: 29000 Open source
20232023-12-31	Free cash flow	-50222000	Operating Cash Flow: -50222000 Open source Capital Expenditure: 0 Open source
20242024-12-31	Free cash flow	-122783000	Operating Cash Flow: -122203000 Open source Capital Expenditure: 580000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

56.9% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	9.5%	Total Liabilities: 19352000 Open source Total Assets: 204206000 Open source
20212021-12-31	Liabilities / assets	20.7%	Total Liabilities: 38582000 Open source Total Assets: 186587000 Open source
20222022-12-31	Liabilities / assets	11.2%	Total Liabilities: 29002000 Open source Total Assets: 259468000 Open source
20232023-12-31	Liabilities / assets	19.1%	Total Liabilities: 58841000 Open source Total Assets: 308124000 Open source
20242024-12-31	Liabilities / assets	56.9%	Total Liabilities: 269683000 Open source Total Assets: 474242000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

10.63× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	14.26×	Current Assets: 202504000 Open source Current Liabilities: 14203000 Open source
20212021-12-31	Current assets / current liabilities	5.09×	Current Assets: 170063000 Open source Current Liabilities: 33422000 Open source
20222022-12-31	Current assets / current liabilities	12.77×	Current Assets: 242996000 Open source Current Liabilities: 19029000 Open source
20232023-12-31	Current assets / current liabilities	33.33×	Current Assets: 289708000 Open source Current Liabilities: 8692000 Open source
20242024-12-31	Current assets / current liabilities	10.63×	Current Assets: 453572000 Open source Current Liabilities: 42681000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 40.56 million Exact value Exact value: -40561000 USD 2019-01-01 – 2019-12-31: -40561000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Verona Pharma PLC · 2019-12-31 Verona Pharma PLC (edgar:1657312) Net Income: -40561000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -40561000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731221000004/vrna-20201231.htm#1669144 Filing: 000165731221000004 The citation records this snapshot. The page link may show a newer release later.	−USD 42.87 million Exact value Exact value: -42868000 USD 2019-01-01 – 2019-12-31: -42868000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Verona Pharma PLC · 2019-12-31 Verona Pharma PLC (edgar:1657312) Operating Cash Flow: -42868000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -42868000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731221000004/vrna-20201231.htm#1197369 Filing: 000165731221000004 The citation records this snapshot. The page link may show a newer release later.	USD 53,000 Exact value Exact value: 53000 USD 2019-01-01 – 2019-12-31: 53000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Verona Pharma PLC · 2019-12-31 Verona Pharma PLC (edgar:1657312) Capital Expenditure: 53000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 53000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731221000004/vrna-20201231.htm#1200164 Filing: 000165731221000004 The citation records this snapshot. The page link may show a newer release later.	−USD 42.92 million Calculation and evidence -42868000 − 53000 USD Exact free cash flow: -42921000 USD 2019-01-01 – 2019-12-31: -42868000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 53000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Verona Pharma PLC · 2019-12-31 Verona Pharma PLC (edgar:1657312) Free cash flow: -42921000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -42868000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731221000004/vrna-20201231.htm#1197369 Filing: 000165731221000004 Input fundies:CapitalExpenditure: 53000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731221000004/vrna-20201231.htm#1200164 Filing: 000165731221000004 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 65.15 million Exact value Exact value: -65146000 USD 2020-01-01 – 2020-12-31: -65146000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Verona Pharma PLC · 2020-12-31 Verona Pharma PLC (edgar:1657312) Net Income: -65146000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -65146000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731222000010/vrna-20211231.htm#1716958 Filing: 000165731222000010 The citation records this snapshot. The page link may show a newer release later.	−USD 45.08 million Exact value Exact value: -45076000 USD 2020-01-01 – 2020-12-31: -45076000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Verona Pharma PLC · 2020-12-31 Verona Pharma PLC (edgar:1657312) Operating Cash Flow: -45076000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -45076000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731222000010/vrna-20211231.htm#1239285 Filing: 000165731222000010 The citation records this snapshot. The page link may show a newer release later.	USD 82,000 Exact value Exact value: 82000 USD 2020-01-01 – 2020-12-31: 82000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Verona Pharma PLC · 2020-12-31 Verona Pharma PLC (edgar:1657312) Capital Expenditure: 82000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 82000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731222000010/vrna-20211231.htm#1242085 Filing: 000165731222000010 The citation records this snapshot. The page link may show a newer release later.	−USD 45.16 million Calculation and evidence -45076000 − 82000 USD Exact free cash flow: -45158000 USD 2020-01-01 – 2020-12-31: -45076000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 82000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Verona Pharma PLC · 2020-12-31 Verona Pharma PLC (edgar:1657312) Free cash flow: -45158000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -45076000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731222000010/vrna-20211231.htm#1239285 Filing: 000165731222000010 Input fundies:CapitalExpenditure: 82000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731222000010/vrna-20211231.htm#1242085 Filing: 000165731222000010 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 55.57 million Exact value Exact value: -55569000 USD 2021-01-01 – 2021-12-31: -55569000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Verona Pharma PLC · 2021-12-31 Verona Pharma PLC (edgar:1657312) Net Income: -55569000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -55569000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731223000006/vrna-20221231.htm#1772276 Filing: 000165731223000006 The citation records this snapshot. The page link may show a newer release later.	−USD 33.25 million Exact value Exact value: -33254000 USD 2021-01-01 – 2021-12-31: -33254000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Verona Pharma PLC · 2021-12-31 Verona Pharma PLC (edgar:1657312) Operating Cash Flow: -33254000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33254000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731223000006/vrna-20221231.htm#1295268 Filing: 000165731223000006 The citation records this snapshot. The page link may show a newer release later.	USD 12,000 Exact value Exact value: 12000 USD 2021-01-01 – 2021-12-31: 12000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Verona Pharma PLC · 2021-12-31 Verona Pharma PLC (edgar:1657312) Capital Expenditure: 12000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731223000006/vrna-20221231.htm#1298068 Filing: 000165731223000006 The citation records this snapshot. The page link may show a newer release later.	−USD 33.27 million Calculation and evidence -33254000 − 12000 USD Exact free cash flow: -33266000 USD 2021-01-01 – 2021-12-31: -33254000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 12000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Verona Pharma PLC · 2021-12-31 Verona Pharma PLC (edgar:1657312) Free cash flow: -33266000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33254000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731223000006/vrna-20221231.htm#1295268 Filing: 000165731223000006 Input fundies:CapitalExpenditure: 12000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731223000006/vrna-20221231.htm#1298068 Filing: 000165731223000006 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 68.7 million Exact value Exact value: -68701000 USD 2022-01-01 – 2022-12-31: -68701000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Verona Pharma PLC · 2022-12-31 Verona Pharma PLC (edgar:1657312) Net Income: -68701000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -68701000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1835102 Filing: 000165731225000010 The citation records this snapshot. The page link may show a newer release later.	−USD 59.86 million Exact value Exact value: -59862000 USD 2022-01-01 – 2022-12-31: -59862000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Verona Pharma PLC · 2022-12-31 Verona Pharma PLC (edgar:1657312) Operating Cash Flow: -59862000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -59862000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1429902 Filing: 000165731225000010 The citation records this snapshot. The page link may show a newer release later.	USD 29,000 Exact value Exact value: 29000 USD 2022-01-01 – 2022-12-31: 29000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Verona Pharma PLC · 2022-12-31 Verona Pharma PLC (edgar:1657312) Capital Expenditure: 29000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 29000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1432714 Filing: 000165731225000010 The citation records this snapshot. The page link may show a newer release later.	−USD 59.89 million Calculation and evidence -59862000 − 29000 USD Exact free cash flow: -59891000 USD 2022-01-01 – 2022-12-31: -59862000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 29000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Verona Pharma PLC · 2022-12-31 Verona Pharma PLC (edgar:1657312) Free cash flow: -59891000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -59862000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1429902 Filing: 000165731225000010 Input fundies:CapitalExpenditure: 29000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1432714 Filing: 000165731225000010 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 54.37 million Exact value Exact value: -54369000 USD 2023-01-01 – 2023-12-31: -54369000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Verona Pharma PLC · 2023-12-31 Verona Pharma PLC (edgar:1657312) Net Income: -54369000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -54369000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1834327 Filing: 000165731225000010 The citation records this snapshot. The page link may show a newer release later.	−USD 50.22 million Exact value Exact value: -50222000 USD 2023-01-01 – 2023-12-31: -50222000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Verona Pharma PLC · 2023-12-31 Verona Pharma PLC (edgar:1657312) Operating Cash Flow: -50222000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -50222000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1429245 Filing: 000165731225000010 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2023-01-01 – 2023-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Verona Pharma PLC · 2023-12-31 Verona Pharma PLC (edgar:1657312) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1432117 Filing: 000165731225000010 The citation records this snapshot. The page link may show a newer release later.	−USD 50.22 million Calculation and evidence -50222000 − 0 USD Exact free cash flow: -50222000 USD 2023-01-01 – 2023-12-31: -50222000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Verona Pharma PLC · 2023-12-31 Verona Pharma PLC (edgar:1657312) Free cash flow: -50222000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -50222000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1429245 Filing: 000165731225000010 Input fundies:CapitalExpenditure: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1432117 Filing: 000165731225000010 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 173.42 million Exact value Exact value: -173418000 USD 2024-01-01 – 2024-12-31: -173418000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Verona Pharma PLC · 2024-12-31 Verona Pharma PLC (edgar:1657312) Net Income: -173418000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -173418000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1833552 Filing: 000165731225000010 The citation records this snapshot. The page link may show a newer release later.	−USD 122.2 million Exact value Exact value: -122203000 USD 2024-01-01 – 2024-12-31: -122203000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Verona Pharma PLC · 2024-12-31 Verona Pharma PLC (edgar:1657312) Operating Cash Flow: -122203000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -122203000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1428588 Filing: 000165731225000010 The citation records this snapshot. The page link may show a newer release later.	USD 580,000 Exact value Exact value: 580000 USD 2024-01-01 – 2024-12-31: 580000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Verona Pharma PLC · 2024-12-31 Verona Pharma PLC (edgar:1657312) Capital Expenditure: 580000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 580000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1431555 Filing: 000165731225000010 The citation records this snapshot. The page link may show a newer release later.	−USD 122.78 million Calculation and evidence -122203000 − 580000 USD Exact free cash flow: -122783000 USD 2024-01-01 – 2024-12-31: -122203000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 580000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Verona Pharma PLC · 2024-12-31 Verona Pharma PLC (edgar:1657312) Free cash flow: -122783000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T21:54:12Z Snapshot: 31d862154d4ff57ce5c092f286cf1747af2159a50e322ef8e707f92881884b94 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1657312?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -122203000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1428588 Filing: 000165731225000010 Input fundies:CapitalExpenditure: 580000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1657312/000165731225000010/vrna-20241231.htm#1431555 Filing: 000165731225000010 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

89 filings · 1,560 latest values · 1,560 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001657312, 1657312, VRNA, edgar:1657312

Also known as Verona Pharma PLC, Verona Pharma plc

Verona Pharma PLC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation